Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience.

Bekoz, H.; Karadurmus, N.; Paydas, S.; Turker, A.; Toptas, T.; Tuglular, T.; Sonmez, M.; Gulbas, Z.; Tekgunduz, E.; Kaya, A.; Ozbalak, Mustafa; Tastemir, N.; Kaynar, L.; Yildirim, R.; Karadogan, I.; Arat, M.; Tanrikulu, F.; Ozkocaman, V.; Abali, H.; Turgut, M.; Yuksel, M.; Ozcan, M.; Dogu, M.; Hacioglu, S.; Barista, I.; Demirkaya, M.; Koseoglu, F.; Toprak, S.; Yilmaz, M.; Demirkurek, H.; Demirkol, O.; Ferhanoglu, B.

doi:10.1093/annonc/mdx341

Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience.

Bekoz H., Karadurmus N., Paydas S., Turker A., Toptas T., Tuglular T. F., ...Daha Fazla

Annals of oncology : official journal of the European Society for Medical Oncology, cilt.28, sa.10, ss.2496-2502, 2017 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 28 Sayı: 10
Basım Tarihi: 2017
Doi Numarası: 10.1093/annonc/mdx341
Dergi Adı: Annals of oncology : official journal of the European Society for Medical Oncology
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.2496-2502
Anahtar Kelimeler: Hodgkin lymphoma, resistant/relapsed disease, programmed death 1 (PD-1) blocker, nivolumab, BRENTUXIMAB VEDOTIN, PD-1 BLOCKADE
İstanbul Üniversitesi Adresli: Evet

Özet

Background: Reed-Sternberg cells of classical Hodgkin's lymphoma (cHL) are characterized by genetic alterations at the 9p24.1 locus, leading to over-expression of programmed death-ligand 1 and 2. In a phase 1b study, nivolumab, a PD-1-blocking antibody, produced a high response in patients with relapsed or refractory cHL, with an acceptable safety profile.